Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Ischaemic heart disorders; Obesity; Prediabetic state; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 08 Jul 2013 Primary endpoint 'Bodyweight-reduction' has been met.
- 22 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 12 Feb 2013 New trial record